Page last updated: 2024-11-05
ticlopidine and Aortic Incompetence
ticlopidine has been researched along with Aortic Incompetence in 1 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "The mean aortic regurgitation grade was unchanged." | 2.72 | Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. ( Buellesfeld, L; Felderhoff, T; Gerckens, U; Grube, E; Iversen, S; Laborde, JC; Menichelli, M; Mueller, R; Sauren, B; Schmidt, T; Stone, GW; Zickmann, B, 2006) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Grube, E | 1 |
| Laborde, JC | 1 |
| Gerckens, U | 1 |
| Felderhoff, T | 1 |
| Sauren, B | 1 |
| Buellesfeld, L | 1 |
| Mueller, R | 1 |
| Menichelli, M | 1 |
| Schmidt, T | 1 |
| Zickmann, B | 1 |
| Iversen, S | 1 |
| Stone, GW | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| CoreValve® System Australia/New Zealand Clinical Study[NCT01015612] | | 634 participants (Actual) | Interventional | 2008-08-31 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
All-Cause Mortality
is defined per Valve Academic Research Consortium-1 consensus document (VARC-1), including Cardiovascular and non-cardiovascular mortality. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|
| Medtronic CoreValve® System Implantation | 0.038 |
Cardiac-related Death
Defined as all death resulting from a cardiac cause or complications of a cardiac procedure and / or death of an unknown cause; this category includes valve-related deaths and non-valve-related cardiac deaths (e.g. congestive heart failure, acute myocardial infarction, documented fatal arrhythmias). (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|
| Medtronic CoreValve® System Implantation | 0.035 |
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) Rate
Defined as a composite of all cause death, myocardial infarction(MI) (Q-wave & non-Q-wave), stroke, and re-intervention (defined as any emergent cardiac surgery or percutaneous re-intervention catheter procedure that repairs, otherwise alters or adjusts or replaces a previously implanted valve) (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|
| Medtronic CoreValve® System Implantation | 0.099 |
Myocardial Infarction
Included Q-wave and non-Q-wave. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|
| Medtronic CoreValve® System Implantation | 0.021 |
Percentage of Participants With Overall Device Success
"Vascular access, delivery and deployment of the device, and retrieval of the delivery system~Correct position of the device in the proper anatomical location (placement in the annulus with no impedance on device function)~Intended performance of the prosthetic valve (aortic valve area > 1.2 cm2 (by echocardiography using the continuity equation) and mean aortic valve gradient < 20 mmHg, without moderate or severe prosthetic valve aortic regurgitation)~Only one valve implanted~No occurrence of in-hospital MACCE" (NCT01015612)
Timeframe: 24-48 hours after the procedure or before the discharge
| Intervention | % of participants with device success (Number) |
|---|
| Medtronic CoreValve® System Implantation | 52.6 |
Re-intervention
Any emergent surgical or percutaneous interventional catheter procedure that repairs, otherwise alters or adjusts, or replaces a previously implanted valve. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|
| Medtronic CoreValve® System Implantation | 0.019 |
Stroke
Is a neurological deficit lasting more than 24 hours, or lasting 24 hours or less with a brain imaging study showing infarction. (NCT01015612)
Timeframe: 30 days
| Intervention | probability of events at 30 days (Number) |
|---|
| Medtronic CoreValve® System Implantation | 0.043 |
Trials
1 trial available for ticlopidine and Aortic Incompetence